A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic lesions only. Serum amylase and lipase levels were 35 U/L and 191 U/L, respectively. The patient was diagnosed with sorafenib-induced acute pancreatitis. After 10 days of discontinuing sorafenib he still complained of nausea and loss of appetite. Esophagogastroduodenoscopy showed a large bulging lesion, which was suspected to cause extrinsic compression on the high body of the gastric anterior wall. Computed tomography scan revealed a cystic lesion, 8.3 cm in size, in the pancreatic tail, suggesting a pancreatic pseudocyst. After the withdrawal of sorafenib, systemic chemotherapy with Adriamycin and cisplatin was administered. Four months after the discontinuation of sorafenib, the size of the pancreatic pseudocyst decreased from 8.3 cm to 3 cm. The patient's symptoms were also relieved. (J Liver Cancer 2019;19:154-158) 
IntroductIon
Sorafenib, a multi-tyrosine kinase inhibitor, is an orally administered, molecular targeted therapeutic agent that inhibits Raf kinase, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. It has been the only standard therapy that was proven to improve survival in advanced hepatocellular carcinoma before the introduction of newer molecular targeted therapeutic agents. 1 The common side effects of sorafenib include systemic symptoms such as fatigue, skin manifestations such as hand-foot skin reaction, and alopecia. 2 However, nausea, vomiting, and other common gastrointestinal symptoms are uncommon, and cases of acute pancreatitis are rare. 3 In this article, we report a case of acute pancreatitis and pancreatic pseudocyst after sorafenib treatment in a patient with advanced hepatocellular carcinoma. cASE rEPort 
Clinical and laboratory findings

Management, progress, and final diagnosis
After the initial examination, the patient's abdominal pain was suspected to be 1) acute gastritis due to sorafenib administration, 2) acute pancreatitis associated with sorafenib, or 3) acute biliary pancreatitis or cholangitis due to the gallbladder sludge which was either related or unrelated to sorafenib administration. We therefore decided to 1) discontinue sorafenib 
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Volume 19 Number 2, September 2019 kinetics. Endoscopy was additionally performed, and the endoscopic findings showed no significant changes in the esophageal varices and reflux esophagitis as well as portal hypertensive gastropathy compared to the findings 9 months ago. However, a new large bulging mass, occupying the gastric lumen from the anterior wall of the upper body to the fundus, was observed, and was suspected to cause extrinsic compression (Fig. 1) . A CT scan of the abdomen revealed a new cystic lesion, about 8 cm in size, with necrosis of the pancreatic tail parenchyma, which was diagnosed as a pseudocyst of the pancreas ( Fig. 2A, B ). As the abdominal pain resolved and there were no signs of infection, the lesion was monitored for spontaneous resolution without further interventions.
Follow-up outcomes
The patient's condition improved to 1 point on the Eastern Cooperative Oncology Group Performance Status Scale system, the abdominal pain resolved, and his dietary intake recovered. Sorafenib was discontinued and the treatment was changed to Adriamycin and cisplatin systemic chemotherapy. One month later, the CT scan showed that the size of the pseudocyst in the pancreatic tail decreased to about 7 cm. It was planned that the patient would maintain systemic che- (Fig. 2C, D) .
dIScuSSIon
The levels of lipase and amylase are elevated in about 30-40% of patients after taking sorafenib, but acute pancreatitis is a rare occurrence, with <1% incidence. 4 It is to be noted that only a few sporadic cases have been reported to date. 5, 6 The mechanism by which sorafenib induces pancreatitis has been linked to the anti-vascular endothelial growth factor activity of sorafenib. This leads to ischemia of the acinar cells, resulting in acinar cell apoptosis. 7, 8 It has also been argued The patient was subsequently diagnosed with a pseudocyst resulting as a complication of pancreatitis, 4 weeks after the first symptom appeared. This is consistent with the fact that the associated complications usually appear more than four weeks after the onset of pancreatitis. 11 In this case, it was difficult to rule out the possibilities of both cholangitis and pancreatitis being associated with the sludge, because the sludge was observed in the gallbladder on ultrasonography. However, we did not observe any abnormalities in the bile ducts and pancreas on CT, and there was no obstructive jaundice or fever, which are common in cholangitis. If the results of a biochemical test continued to worsen, such as the levels of bilirubin or pancreatic enzymes elevated, even after the discontinuation of sorafenib, then either magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography would have to be performed for evaluating any diseases in the bile duct.
In this case, the pseudocyst was not detected by abdominal ultrasonography at the time of the first visit to the emergency room. This may be due to the differences in sensitivity between ultrasound and CT in pancreatic diseases rather than the possibility of lesions occurring within a week. 12, 13 Most cases of acute pancreatitis reported so far have shown improvement upon discontinuation of the causative agent and administration of conservative treatment. However, pseudocysts may lead to fatal consequences such as secondary infections, complications such as peritonitis due to ruptured cysts, and formation of pseudoaneurysms and bleeding, requiring clinicians to pay attention during treatment with sorafenib.
In conclusion, this is a rare case of acute pancreatitis and pancreatic pseudocyst caused by sorafenib treatment in a patient with advanced hepatocellular carcinoma. It should be kept in mind that these complications are very rare but can be fatal in some cases. In patients with elevated pancreatic enzymes and clinical symptoms suggestive of acute pancreatitis, CT imaging rather than ultrasonography should provide a more accurate and faster diagnosis.
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